Home › Compare › MCFUF vs ABBV
MCFUF yields 67.97% · ABBV yields 3.06%● Live data
📍 MCFUF pulled ahead of the other in Year 1
Combined, MCFUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MCFUF + ABBV for your $10,000?
Micro Focus International plc operates in the enterprise software business in the United Kingdom, the United States, Germany, Canada, France, Japan, and internationally. It offers infrastructure software products that are managed on a portfolio. The company's product portfolio includes sector-agnostic products, such as application modernization and connectivity solutions that help customers to unlock the value from core business applications for modernization, which enable a transformational journey to deliver ongoing value and flexibility from IT investments, on or off the mainframe; application delivery management solutions that helps customers to increase velocity, remove bottlenecks, and deliver high-performing applications to support their digital business; and IT operations management solutions for service assurance, automate the service fulfilment life cycle, and strengthen IT service governance. It also offers CyberRes, a security solution that helps enterprises to create cyber resilience through detecting threats, securing data and applications, and protecting identities, which enables customers to adapt and evolve for the future; and information management and governance solutions that helps customers to analyze, understand, and control data to derive value and manage enterprise risk. The company was founded in 1976 and is headquartered in Newbury, the United Kingdom.
Full MCFUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.